Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine for Suicidal Ideation in Comorbid Depression and Alcohol Abuse
NCT03539887Phase 3Completed
- Sponsor
- UTHealth Houston
- Start
- May 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ketamine in suicidal ideation, major depressive disorder (MDD), bipolar disorder (BD), sponsored by UTHealth Houston. Started May 2018; status: completed.
02
Drugs
ketamine
03
Conditions
suicidal ideationmajor depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03539887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03539887.